FY26 consensus $14.21. The company’s 2026 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the first quarter of 2026, as both cannot be reliably forecasted.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Options Volatility and Implied Earnings Moves Today, April 29, 2026
- These Are the Stocks Reporting Earnings Today – April 29, 2026
- Notable companies reporting before tomorrow’s open
- AbbVie submits application to FDA for new indication for upadacitinib
- AbbVie submits application to FDA for Skyrizi for subcutaneous induction